Wall Street Zen Downgrades Kamada (NASDAQ:KMDA) to Buy

Kamada (NASDAQ:KMDA) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently weighed in on KMDA. HC Wainwright boosted their target price on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday. Stifel Nicolaus set a $11.00 price objective on shares of Kamada in a report on Wednesday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Kamada presently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Kamada Price Performance

Kamada stock opened at $8.70 on Friday. The stock has a market cap of $500.29 million, a PE ratio of 24.86, a P/E/G ratio of 0.76 and a beta of 0.94. The stock’s fifty day moving average is $8.44 and its two-hundred day moving average is $7.46. Kamada has a 1-year low of $5.54 and a 1-year high of $9.35.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Kamada had a return on equity of 7.80% and a net margin of 11.19%.The business had revenue of $44.68 million for the quarter, compared to analyst estimates of $145.07 million. On average, research analysts expect that Kamada will post 0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in Kamada during the first quarter worth approximately $582,000. Goldman Sachs Group Inc. acquired a new stake in shares of Kamada in the first quarter valued at approximately $497,000. Essex Investment Management Co. LLC boosted its holdings in shares of Kamada by 22.4% in the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock valued at $2,751,000 after acquiring an additional 72,602 shares during the period. Arrowstreet Capital Limited Partnership purchased a new position in shares of Kamada during the second quarter worth approximately $472,000. Finally, Bank of America Corp DE grew its position in shares of Kamada by 201.0% during the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after acquiring an additional 41,111 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.